Legal restrictions on off-label promotion of drugs are being challenged in the courts as a violation of First Amendment protection of “commercial speech.” The authors argue that public health concerns make pharmaceutical promotion different from other commercial speech and that more stringent regulation should be permitted.
No takes yet. Share an insight, caveat, or question.
Kesselheim et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: